Diligence memo · auto-generated · as of July 2, 2026
INVO Bioscience, Inc.
INVO Bioscience, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
INVO Bioscience, Inc. operates in Biotech, based in SARASOTA.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
INVO Bioscience, Inc. has raised $7.8M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.5M on 2020-05-15.
Most recent recorded round closed around 2023-03-23.
Valuation (modeled)modeled
Provath models INVO Bioscience, Inc. at approximately $29M (range $2.1M–$110M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.21× the median modeled value of Seed Biotech companies in 2022–2024 (6 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 27 months.
Last raise 3.3 yr ago; this sector typically re-raises about every 11 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 9.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 84% of Biotech peers (233 compared).
Modeled value ranks above 78% of those peers.
Closest niche peers: Yemaachi, General Genomics Inc., MET Biotechnology Inc., J3 Bioscience, Inc., Psycheceutical Bioscience, Inc..
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.